Last €11.69 EUR
Change Today +0.09 / 0.78%
Volume 0.0
TAY On Other Exchanges
As of 2:09 AM 10/23/14 All times are local (Market data is delayed by at least 15 minutes).

mitsubishi tanabe pharma (TAY) Snapshot

Previous Close
Day High
Day Low
52 Week High
10/8/14 - €12.05
52 Week Low
04/11/14 - €9.58
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

mitsubishi tanabe pharma (TAY) Related Businessweek News

No Related Businessweek News Found

mitsubishi tanabe pharma (TAY) Details

Mitsubishi Tanabe Pharma Corporation manufactures and sells pharmaceuticals in Japan and internationally. The company offers autoimmune drugs, including Remicade agent for rheumatoid arthritis and Crohn’s disease, Bechet’s disease with refractory uveoretinitis, psoriasis, ankylosing spondylitis, and ulcerative colitis; and Simponi agent for rheumatoid arthritis. It also provides drugs for diabetes and kidney diseases, such as Kremezin agent for chronic renal failure; and Tanatril agent for hypertension and diabetic nephropathy with type I diabetes mellitus, etc. In addition, the company offers drugs for central nervous system diseases comprising Radicut, a cerebral neuroprotectant; Ceredist agent for spinocerebellar degeneration; Depas, an anti-anxiety agent; and Lexapro, an anti-depressant agent. Further, it provides Maintate agent for treatment of hypertension, angina pectoris, ventricular extrasystole, chronic heart failure, and atrial fibrillation; Talion agent for allergic disorders; Urso agent for the improvement of hepatic, biliary, and digestive function; Anplag, an anti-platelet agent; and Herbesser, an agent for angina pectoris and hypertension. Additionally, the company offers vaccines, such as TETRABIK, a combined vaccine for diphtheria, pertussis, tetanus, and poliomyelitis; and influenza. It also provides over-the-counter products, including herbal and digestive medicines, as well as oral solutions for tonic and nutritional supplement; oral agent for allergic rhinitis; and products for the treatment of skin conditions and recurrent vaginal candidiasis. The company also offers pharmaceutical information and real estate management services; sells generic pharmaceuticals, chemicals, etc.; invests in bio-ventures; and is involved in distribution and warehouse operations. The company was founded in 1678 and is headquartered in Osaka, Japan. Mitsubishi Tanabe Pharma Corporation is a subsidiary of Mitsubishi Chemical Holdings Corporation.

9,065 Employees
Last Reported Date: 06/20/14
Founded in 1678

mitsubishi tanabe pharma (TAY) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

mitsubishi tanabe pharma (TAY) Key Developments

AstraZeneca and Mitsubishi Tanabe Pharma Corporation Announce Research Collaboration in Diabetic Nephropathy

AstraZeneca and Mitsubishi Tanabe Pharma Corporation, or MTPC, have announced three-year research collaboration in the area of diabetic nephropathy. The aim of the research collaboration is to leverage complementary strengths, expertise and assets to validate and progress novel research targets and molecules into clinical development. The collaboration will span from target selection up to the delivery of small molecule candidate drugs. Targets from each company's early research portfolios have been identified as approaches of common interest and additional targets may be included under the collaboration at a later stage, if mutually desired. The research will be performed in parallel at AstraZeneca's Cardiovascular and Metabolic Disease Innovative Medicines Unit (CVMD iMed) in Molndal, Sweden, and at MTPC's facilities in Japan. The parties believe that the collaboration will yield high quality candidate drugs much faster than working alone. There is no financial commitment for the research involved and each party will contribute equal resource at their own cost.

Mitsubishi Thnabe Pharma Collaborates with Astrazeneca for Conducting Research on Diabetic Nephropathy

Mitsubishi Thnabe Pharma has collaborated with AstraZeneca. It was reported on August 21, 2014 that the collaboration is aimed at conducting research on diabetic nephropathy. The three-year research is intended to leverage complementary strengths, expertise and assets to certify and progress new research targets and molecules into clinical development. It will be executed in parallel at Mitsubishi Thnabe Pharma's facilities in Japan, and at AstraZeneca's Cardiovascular and Metabolic Disease Innovative Medicines Unit in Moindal, Sweden.

Mitsubishi Tanabe Pharma Corporation Reports Financial Results for the First Quarter Ended June 30, 2014; Provides Earnings Guidance for the First Half and Full Year of Fiscal 2014

Mitsubishi Tanabe Pharma Corporation reported financial results for the first quarter ended June 30, 2014. Net income per share was JPY 17.09 per share compared to JPY 18.56 per share, for the same quarter ended June 30, 2013. Gross profit for the first quarter ended June 30, 2014 was JPY 55.37 billion, compared to JPY 60.39 billion for the same quarter ended June 30, 2013. For first half of fiscal 2014, the company expects net sales to be JPY 201 billion, net income to be JPY 21 billion, or JPY 37.43 per share and operating income to be JPY 29.5 billion. For fiscal 2014, the company expects net sales to be JPY 409 billion, net income to be JPY 40.5 billion, or JPY 72.19 per share and operating income to be JPY 60 billion.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TAY:GR €11.69 EUR +0.09

TAY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TAY.
View Industry Companies

Industry Analysis


Industry Average

Valuation TAY Industry Range
Price/Earnings 19.1x
Price/Sales 2.1x
Price/Book 1.1x
Price/Cash Flow 15.0x
TEV/Sales 1.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MITSUBISHI TANABE PHARMA, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at